Member Posts > Cardiol Therapeutics' CRD-38: A Pioneering Subcutaneous Therapy for Heart Failure
📢 Cardiol Therapeutics (NASDAQ: CRDL) has unveiled compelling preclinical results in JACC, demonstrating CRD-38's efficacy in addressing key drivers of heart failure.
💊 The Science Behind CRD-38
✔ CBD Action: Anti-inflammatory and anti-fibrotic effects help reduce disease progression.
✔ Organic Nitrates: Improve oxygen supply, leading to better cardiovascular function.
🔬 Key Study Findings:
📈 Boosted Ejection Fraction - More efficient blood circulation.
📉 Lower Fibrosis & Inflammation - Less structural damage to the heart.
💡 Why This Is a Game-Changer:
With many HF patients already on multiple oral meds, CRD-38's subcutaneous administration could improve adherence and effectiveness.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx